Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy

Nice Bedini, Alessandro Cicchetti, Federica Palorini, Tiziana Magnani, Valentina Zuco, Marzia Pennati, Elisa Campi, Paola Allavena, Samantha Pesce, Sergio Villa, Barbara Avuzzi, Sara Morlino, Maria Emanuela Visentin, Nadia Zaffaroni, Tiziana Rancati, Riccardo Valdagni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.

Original languageEnglish
Article number9128128
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Radiotherapy
Prostatic Neoplasms
Toxicity
Surgery
Plasmas
CXC Chemokines
Molecules
Chemokine CCL2
Interleukin-3
Radiation Tolerance
Interleukin-8
Linear regression
Anticoagulants
Linear Models
Interleukin-6
Tumor Necrosis Factor-alpha
Cytokines
Hypertension
Monitoring

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy. / Bedini, Nice; Cicchetti, Alessandro; Palorini, Federica; Magnani, Tiziana; Zuco, Valentina; Pennati, Marzia; Campi, Elisa; Allavena, Paola; Pesce, Samantha; Villa, Sergio; Avuzzi, Barbara; Morlino, Sara; Visentin, Maria Emanuela; Zaffaroni, Nadia; Rancati, Tiziana; Valdagni, Riccardo.

In: Disease Markers, Vol. 2018, 9128128, 01.01.2018.

Research output: Contribution to journalArticle

@article{d20bcb530cdf4166851e083108995e90,
title = "Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy",
abstract = "A recent {"}hot topic{"} in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.",
author = "Nice Bedini and Alessandro Cicchetti and Federica Palorini and Tiziana Magnani and Valentina Zuco and Marzia Pennati and Elisa Campi and Paola Allavena and Samantha Pesce and Sergio Villa and Barbara Avuzzi and Sara Morlino and Visentin, {Maria Emanuela} and Nadia Zaffaroni and Tiziana Rancati and Riccardo Valdagni",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/9128128",
language = "English",
volume = "2018",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy

AU - Bedini, Nice

AU - Cicchetti, Alessandro

AU - Palorini, Federica

AU - Magnani, Tiziana

AU - Zuco, Valentina

AU - Pennati, Marzia

AU - Campi, Elisa

AU - Allavena, Paola

AU - Pesce, Samantha

AU - Villa, Sergio

AU - Avuzzi, Barbara

AU - Morlino, Sara

AU - Visentin, Maria Emanuela

AU - Zaffaroni, Nadia

AU - Rancati, Tiziana

AU - Valdagni, Riccardo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.

AB - A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.

UR - http://www.scopus.com/inward/record.url?scp=85048604844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048604844&partnerID=8YFLogxK

U2 - 10.1155/2018/9128128

DO - 10.1155/2018/9128128

M3 - Article

C2 - 29682101

AN - SCOPUS:85048604844

VL - 2018

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 9128128

ER -